Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.
|Articles|September 28, 2015
Shelagh Wright Discusses Components of Pain
Author(s)Shelagh Wright, PhD
Shelagh Wright, PhD, a retired lecturer from Dublin City University, discusses components of pain.
Advertisement
Shelagh Wright, PhD, a retired lecturer from Dublin City University, discusses components of pain.
Pain is a complex experience that needs to be addressed from a biopsychosocial model, Wright says.
Whether pain is acute, chronic, malignant, or nonmalignant, physical and psychological components interact with each other and cannot be split when treating pain.
Advertisement
Related to this article
Dana-Farber nurse practitioners outline ADC patient selection, sequencing, ILD surveillance, and patient education from JADPRO Live 2026.
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.
At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
AI Breast Cancer Risk Models Guide Triage and Nurse-Led Patient Counseling
2
Sunvozertinib Now Available in US for Pretreated EGFR Exon 20+ NSCLC
3
What Oncology Nurses Need to Know About ADCs in Breast Cancer
4
FDA Grants Traditional Approval to Pembrolizumab in TMB-H Solid Tumors
5